Mehmet Asim Bilen, MD
Assistant Professor, Hematology & Medical Oncology
Emory University School of Medicine
Office: The Emory Clinic, Bldg. B
Phone: (404) 778-3460
For all patient inquiries or appointment requests, please dial (404) 778-1900.
Mehmet Asim Bilen, MD, is a clinical investigator in the Division of Medical Oncology with a disease focus in genito-urinary cancers. Dr. Bilen works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Grady Clinical Research Committee.
Dr. Bilen received his MD from Hacettepe University Faculty of Medicine in Ankara, Turkey. He completed a postdoctoral fellowship in Molecular Pathology and a clinical fellowship in Hematology/Oncology at University of Texas MD Anderson Cancer Center in Houston, Texas. His postgraduate medical education also included residency training at Baylor College of Medicine in Houston, Texas.
He holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
As a postdoctoral fellow at University of Texas MD Anderson Cancer Center, Dr. Bilen worked with Dr. Sue-Hwa Lin on developing biomarkers and therapeutic strategies that can be applied in clinical settings to promote early detection and to improve treatment options for prostate cancer bone metastasis. He focused on the role of cadherin-11 in prostate cancer bone metastasis and generating monoclonal antibodies that inhibited that metastasis. He showed that inhibition of cell adhesion by a cadherin-11 antibody thwarts prostate cancer bone metastasis and monotherapy using a cadherin-11 antibody is a suitable option for prevention.
Dr. Bilen continued to focus on genitourinary malignancies after becoming a clinical fellow at UT MD Anderson Cancer Center where he worked on several projects in clinical and translational research. In 2015, he was selected to participate in the AACR/ASCO Vail workshop.
- View publications on Pubmed
Dr. Bilen has published more than 25 peer-reviewed original papers and reviews in leading journals including Cancer Research, Molecular Cancer Research, FASEB J, Journal of Pathology, Cancer and Clinical and Experimental Metastasis and has authored or co-authored more than 15 abstracts for presentations at professional meetings.